Developer docs
API playgroundTry for free, no card

Search company profiles

Vifor Pharma

Full company profile

uuid0004hao

Namestring
Vifor Pharma
Legal namestring
Vifor Pharma (now operating as CSL Vifor)
Websiteurl
viforpharma.com
Company typeenum
Private
Founded yearint
1872
Descriptiontext

Vifor Pharma, now operating as CSL Vifor following CSL Limited's August 2022 acquisition, is a Switzerland-headquartered specialty pharmaceutical company focused on iron deficiency and nephrology therapies. The company's origins trace to 1872 when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, giving it over 150 years of heritage in pharmaceutical compounding and therapeutics. CSL Vifor maintains manufacturing operations in St. Gallen and Ettingen, Switzerland, with R&D laboratories in Schlieren, and markets products in over 100 countries globally as a business unit within CSL Limited (ASX-listed parent).

Short descriptiontext

CSL Vifor (formerly Vifor Pharma) is a Swiss specialty pharmaceutical company and CSL Limited business unit developing iron deficiency and nephrology therapies marketed across more than 100 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGlattbrugg, Switzerland
HQ citystring
Glattbrugg
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iron deficiency therapy, nephrology pharmaceuticals, intravenous iron, kidney disease treatment, iron supplementation
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Iron Deficiency and Nephrology)
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 13 records shown
1Ferinject
Description

Ferric Carboxymaltose Intravenous Iron - Approved in 87 countries. Also marketed as Injectafer in the USA.

csl.com
+12 more records
Core offering1 text field

CSL Vifor (formerly Vifor Pharma) is a Swiss-based pharmaceutical company that develops, manufactures, licenses, and markets specialty medicines for iron deficiency, iron deficiency anaemia, and kidney disease. Its portfolio spans intravenous and oral iron therapies, potassium and phosphate binders, erythropoiesis-stimulating agents, and specialty nephrology drugs, with products approved in up to 87 countries and marketed across more than 100 countries. The company operates via the joint venture Vifor Fresenius Medical Care Renal Pharma and in-licenses products from partners such as Roche and Pfizer.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CSL Vifor is a global pharmaceutical company specializing in iron deficiency and nephrology therapies. The company's product portfolio consists of two core therapeutic areas: Iron Deficiency (including Ferinject®, Venofer®, and Maltofer®) and Nephrology (including Veltassa®, Rayaldee®, Tavneos®, Mircera®, Retacrit®, Velphoro®, Korsuva®, and Filspari®). CSL Vifor also partners with Vifor Fresenius Medical Care Renal Pharma for renal care. The company markets products across over 100 countries globally and focuses on precision healthcare through strategic global partnering, in-licensing, manufacturing, and marketing of pharmaceutical products.

Product and service11 records
1Ferinject® / Injectafer®
CategoryIron deficiency therapy
Description

Ferric Carboxymaltose intravenous iron therapy for iron deficiency and iron deficiency anaemia, approved in 87 countries and marketed as Injectafer® in the USA.

2Venofer®
CategoryIron deficiency therapy
Description

Iron Sucrose low-dose intravenous iron therapy for iron deficiency, approved in 85 countries.

3Maltofer®
CategoryIron deficiency therapy
Description

Oral Iron Polymaltose Complex for iron deficiency therapy, approved in 76 countries.

4Veltassa®
CategoryNephrology therapy
Description

Patiromer medication for hyperkalemia management in nephrology, available in 16 countries.

5Rayaldee®
CategoryNephrology therapy
Description

Prolonged-release formulation of Calcifediol for management of chronic kidney disease patients with secondary hyperparathyroidism. Received marketing authorization in all European countries applied for including Switzerland; launched in Germany and Switzerland.

6Tavneos®
CategoryNephrology therapy
Description

Avacopan, oral elective inhibitor of C5aR1 for ANCA-associated vasculitis. Approved in EU, UK, Switzerland, Australia, UAE, Kuwait, Israel and launched in major EU markets, Australia, Japan and Canada.

7Mircera®
CategoryNephrology therapy
Description

Long-acting Erythropoiesis-stimulating Agent for anemia management in chronic kidney disease. Licensed from F. Hoffmann-La Roche AG since 2015 and supplied to over 6,500 dialysis clinics in the USA and its territories.

8Retacrit®
CategoryNephrology therapy
Description

Epoetin Alfa-epbx for anemia treatment. Licensed from Pfizer, Inc. and approved in the USA since 2018 for all indications of its reference drug, epoetin alfa.

9Velphoro®
CategoryNephrology therapy
Description

Sucroferric Oxyhydroxide phosphate binder for hyperphosphatemia management in chronic kidney disease patients on dialysis, approved in 50 countries.

10Korsuva® / Kapruvia®
CategoryNephrology therapy
Description

Difelikefalin, peripherally restricted kappa opioid receptor agonist for pruritus (itch) in hemodialysis patients. Also marketed as Kapruvia®. Approved in US, EU, UK, Switzerland, Canada, Australia, UAE, Kuwait, Israel and Singapore.

11Filspari®
CategoryNephrology therapy
Description

Treatment for primary immunoglobulin A (IgA) nephropathy. Approved in EU, UK, Switzerland and launched in Germany, UK, Austria and Switzerland.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2015-01-01
Description

Licensing partner for Mircera (long-acting erythropoiesis-stimulating agent) since 2015. Product currently supplied to over 6,500 dialysis clinics in the USA and its territories.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint company partnership combining CSL Vifor's iron deficiency expertise with nephrology focus. Together they have a strong and rapidly growing presence in nephrology, committed to launching next generation of therapies to address the full spectrum of kidney disease.

3Kissei Pharmaceutical
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional partner for Tavneos (avacopan) launch in Japan.

csl.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional partner for Tavneos (avacopan) launch in Canada and Korsuva (difelikefalin) distribution in Canada.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

CSL Seqirus manages Tavneos (avacopan) distribution in Australia.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partner for Korsuva (difelikefalin) distribution in UAE, Kuwait and Israel.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Akebia directly competes through vadadustat (Auryxia/ferric citrate for hyperphosphatemia competes with Velphoro; HIF-PH inhibitor vadadustat competes in CKD anemia space with Mircera). Comparable as a focused nephrology therapeutics company targeting CKD-MBD and anemia.

TypeDirect peer
Description

Fresenius Medical Care is both JV partner (Vifor Fresenius Medical Care Renal Pharma) and an adjacent comparable, providing the global dialysis clinic network through which CSL Vifor nephrology products reach patients. Comparable as a vertically integrated kidney care player where CSL Vifor's product portfolio complements FMC's services business.

TypeDirect peer
Description

Amgen directly competes with CSL Vifor in nephrology through Epogen/Aranesp (ESAs competing with Mircera), acquired ChemoCentryx (originator of avacopan/Tavneos), and markets Sensipar/Mimpara (cinacalcet) for secondary hyperparathyroidism competing with Rayaldee. Comparable as a global biotech with deep nephrology and rare disease franchises.

TypeBroad incumbent
Description

Sanofi competes via its Genzyme rare disease unit (Cerezyme, Fabrazyme, etc.) and through nephrology-relevant assets such as dupilumab for related inflammatory indications. Comparable as a global specialty/rare disease pharma pursuing overlapping patient populations.

TypeBroad incumbent
Description

Roche is both originator/licensor of Mircera (licensed to CSL Vifor since 2015) and a broader pharma player with nephrology adjacencies (including competing anemia therapies). Comparable as a global pharma incumbent whose nephrology franchise intersects CSL Vifor's iron deficiency and CKD-anemia portfolio.

TypeDirect peer
Description

Ardelyx directly competes with CSL Vifor through sparsentan (FILSPARI rival for IgA nephropathy) and tenapanor (Xphozah) for hyperphosphatemia in dialysis patients competing with Velphoro. Closely comparable as a specialty nephrology company with overlapping target indications.

TypeDirect peer
Description

Direct competitor through Lokelma (sodium zirconium cyclosilicate) for hyperkalemia competing with Veltassa, and via Alexion's rare disease portfolio (including IgA nephropathy assets) overlapping with CSL Vifor's nephrology specialty franchise. Comparable as a global pharma with parallel iron deficiency, nephrology, and rare disease strategy.

TypeBroad incumbent
Description

GSK competes in nephrology via dapagliflozin (Farxiga) for CKD, broadly overlapping with CSL Vifor's nephrology franchise, and is a comparable global pharma with a sizeable specialty/rare disease portfolio. Less specialized in iron deficiency but directly competes in CKD outcomes.

TypeDirect peer
Description

Pharmacosmos directly competes with CSL Vifor's iron deficiency franchise through Monoferric (iron isomaltoside) and Diafer (low-dose iron isomaltoside), challenging Ferinject and Venofer in the IV iron market. Closely comparable as a specialty iron deficiency therapeutics company.

TypeDirect peer
Description

Daiichi Sankyo (via American Regent) directly competes with CSL Vifor by marketing Injectafer (ferric carboxymaltose) in the US — the same molecule as CSL Vifor's Ferinject. Comparable as a global pharma with a parallel IV iron deficiency franchise in the same therapeutic category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vifor Pharma

Specialty Pharmaceuticals (Iron Deficiency and Nephrology)viforpharma.com

CSL Vifor (formerly Vifor Pharma) is a Swiss specialty pharmaceutical company and CSL Limited business unit developing iron deficiency and nephrology therapies marketed across more than 100 countries.

What Vifor Pharma does

Vifor Pharma, now operating as CSL Vifor following CSL Limited's August 2022 acquisition, is a Switzerland-headquartered specialty pharmaceutical company focused on iron deficiency and nephrology therapies. The company's origins trace to 1872 when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, giving it over 150 years of heritage in pharmaceutical compounding and therapeutics. CSL Vifor maintains manufacturing operations in St. Gallen and Ettingen, Switzerland, with R&D laboratories in Schlieren, and markets products in over 100 countries globally as a business unit within CSL Limited (ASX-listed parent).

Vifor Pharma firmographics

Firmographics
Name
Vifor Pharma
Legal name
Vifor Pharma (now operating as CSL Vifor)
Website
https://viforpharma.com
Company type
Private
Founded year
1872
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
CSL Vifor (formerly Vifor Pharma) is a Swiss specialty pharmaceutical company and CSL Limited business unit developing iron deficiency and nephrology therapies marketed across more than 100 countries.
Ownership category
akta.pro rank

Where Vifor Pharma is headquartered

Location

Headquarters

HQ city
Glattbrugg
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Vifor Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels4 records

Vifor Pharma product offering

Product offering

Core offering

CSL Vifor (formerly Vifor Pharma) is a Swiss-based pharmaceutical company that develops, manufactures, licenses, and markets specialty medicines for iron deficiency, iron deficiency anaemia, and kidney disease. Its portfolio spans intravenous and oral iron therapies, potassium and phosphate binders, erythropoiesis-stimulating agents, and specialty nephrology drugs, with products approved in up to 87 countries and marketed across more than 100 countries. The company operates via the joint venture Vifor Fresenius Medical Care Renal Pharma and in-licenses products from partners such as Roche and Pfizer.

Product overview

CSL Vifor is a global pharmaceutical company specializing in iron deficiency and nephrology therapies. The company's product portfolio consists of two core therapeutic areas: Iron Deficiency (including Ferinject®, Venofer®, and Maltofer®) and Nephrology (including Veltassa®, Rayaldee®, Tavneos®, Mircera®, Retacrit®, Velphoro®, Korsuva®, and Filspari®). CSL Vifor also partners with Vifor Fresenius Medical Care Renal Pharma for renal care. The company markets products across over 100 countries globally and focuses on precision healthcare through strategic global partnering, in-licensing, manufacturing, and marketing of pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Brands

  • Ferinject: Ferric Carboxymaltose Intravenous Iron - Approved in 87 countries. Also marketed as Injectafer in the USA.
  • Injectafer
  • Venofer
  • Maltofer
  • Veltassa
  • Rayaldee
  • Tavneos
  • Mircera
  • Retacrit
  • Velphoro
  • Korsuva
  • Kapruvia
  • Filspari

Products and services

  • Ferinject® / Injectafer® Ferric Carboxymaltose intravenous iron therapy for iron deficiency and iron deficiency anaemia, approved in 87 countries and marketed as Injectafer® in the USA.
  • Venofer® Iron Sucrose low-dose intravenous iron therapy for iron deficiency, approved in 85 countries.
  • Maltofer® Oral Iron Polymaltose Complex for iron deficiency therapy, approved in 76 countries.
  • Veltassa® Patiromer medication for hyperkalemia management in nephrology, available in 16 countries.
  • Rayaldee® Prolonged-release formulation of Calcifediol for management of chronic kidney disease patients with secondary hyperparathyroidism. Received marketing authorization in all European countries applied for including Switzerland; launched in Germany and Switzerland.
  • Tavneos® Avacopan, oral elective inhibitor of C5aR1 for ANCA-associated vasculitis. Approved in EU, UK, Switzerland, Australia, UAE, Kuwait, Israel and launched in major EU markets, Australia, Japan and Canada.
  • Mircera® Long-acting Erythropoiesis-stimulating Agent for anemia management in chronic kidney disease. Licensed from F. Hoffmann-La Roche AG since 2015 and supplied to over 6,500 dialysis clinics in the USA and its territories.
  • Retacrit® Epoetin Alfa-epbx for anemia treatment. Licensed from Pfizer, Inc. and approved in the USA since 2018 for all indications of its reference drug, epoetin alfa.
  • Velphoro® Sucroferric Oxyhydroxide phosphate binder for hyperphosphatemia management in chronic kidney disease patients on dialysis, approved in 50 countries.
  • Korsuva® / Kapruvia® Difelikefalin, peripherally restricted kappa opioid receptor agonist for pruritus (itch) in hemodialysis patients. Also marketed as Kapruvia®. Approved in US, EU, UK, Switzerland, Canada, Australia, UAE, Kuwait, Israel and Singapore.
  • Filspari® Treatment for primary immunoglobulin A (IgA) nephropathy. Approved in EU, UK, Switzerland and launched in Germany, UK, Austria and Switzerland.

Companies that use Vifor Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Vifor Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Vifor Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • F. Hoffmann-La Roche AGcoreTechnology or Integration · 1 January 2015Licensing partner for Mircera (long-acting erythropoiesis-stimulating agent) since 2015. Product currently supplied to over 6,500 dialysis clinics in the USA and its territories.
  • Vifor Fresenius Medical Care Renal PharmacoreStrategic or Co-development PartnerJoint company partnership combining CSL Vifor's iron deficiency expertise with nephrology focus. Together they have a strong and rapidly growing presence in nephrology, committed to launching next generation of therapies to address the full spectrum of kidney disease.
  • Kissei PharmaceuticalminorChannel Partner/ Reseller/ DistributorRegional partner for Tavneos (avacopan) launch in Japan.
  • Otsuka PharmaceuticalminorChannel Partner/ Reseller/ DistributorRegional partner for Tavneos (avacopan) launch in Canada and Korsuva (difelikefalin) distribution in Canada.
  • CSL SeqirusminorChannel Partner/ Reseller/ DistributorCSL Seqirus manages Tavneos (avacopan) distribution in Australia.
  • CTS (Clinaltex)minorChannel Partner/ Reseller/ DistributorPartner for Korsuva (difelikefalin) distribution in UAE, Kuwait and Israel.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Vifor Pharma competitors and assessment

Company assessment

Direct peers

  • Akebia Therapeutics: Akebia directly competes through vadadustat (Auryxia/ferric citrate for hyperphosphatemia competes with Velphoro; HIF-PH inhibitor vadadustat competes in CKD anemia space with Mircera). Comparable as a focused nephrology therapeutics company targeting CKD-MBD and anemia.
  • Fresenius Medical Care: Fresenius Medical Care is both JV partner (Vifor Fresenius Medical Care Renal Pharma) and an adjacent comparable, providing the global dialysis clinic network through which CSL Vifor nephrology products reach patients. Comparable as a vertically integrated kidney care player where CSL Vifor's product portfolio complements FMC's services business.
  • Amgen: Amgen directly competes with CSL Vifor in nephrology through Epogen/Aranesp (ESAs competing with Mircera), acquired ChemoCentryx (originator of avacopan/Tavneos), and markets Sensipar/Mimpara (cinacalcet) for secondary hyperparathyroidism competing with Rayaldee. Comparable as a global biotech with deep nephrology and rare disease franchises.
  • Ardelyx: Ardelyx directly competes with CSL Vifor through sparsentan (FILSPARI rival for IgA nephropathy) and tenapanor (Xphozah) for hyperphosphatemia in dialysis patients competing with Velphoro. Closely comparable as a specialty nephrology company with overlapping target indications.
  • AstraZeneca: Direct competitor through Lokelma (sodium zirconium cyclosilicate) for hyperkalemia competing with Veltassa, and via Alexion's rare disease portfolio (including IgA nephropathy assets) overlapping with CSL Vifor's nephrology specialty franchise. Comparable as a global pharma with parallel iron deficiency, nephrology, and rare disease strategy.
  • Pharmacosmos: Pharmacosmos directly competes with CSL Vifor's iron deficiency franchise through Monoferric (iron isomaltoside) and Diafer (low-dose iron isomaltoside), challenging Ferinject and Venofer in the IV iron market. Closely comparable as a specialty iron deficiency therapeutics company.
  • Daiichi Sankyo / American Regent: Daiichi Sankyo (via American Regent) directly competes with CSL Vifor by marketing Injectafer (ferric carboxymaltose) in the US — the same molecule as CSL Vifor's Ferinject. Comparable as a global pharma with a parallel IV iron deficiency franchise in the same therapeutic category.

Broad incumbents

  • Sanofi: Sanofi competes via its Genzyme rare disease unit (Cerezyme, Fabrazyme, etc.) and through nephrology-relevant assets such as dupilumab for related inflammatory indications. Comparable as a global specialty/rare disease pharma pursuing overlapping patient populations.
  • Roche: Roche is both originator/licensor of Mircera (licensed to CSL Vifor since 2015) and a broader pharma player with nephrology adjacencies (including competing anemia therapies). Comparable as a global pharma incumbent whose nephrology franchise intersects CSL Vifor's iron deficiency and CKD-anemia portfolio.
  • GSK: GSK competes in nephrology via dapagliflozin (Farxiga) for CKD, broadly overlapping with CSL Vifor's nephrology franchise, and is a comparable global pharma with a sizeable specialty/rare disease portfolio. Less specialized in iron deficiency but directly competes in CKD outcomes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Vifor Pharma social profiles

Digital presence

Vifor Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vifor Pharma leadership team

Management profile

Number of profiles

Vifor Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vifor Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vifor Pharma M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vifor Pharma

What does Vifor Pharma do?

CSL Vifor (formerly Vifor Pharma) is a Swiss-based pharmaceutical company that develops, manufactures, licenses, and markets specialty medicines for iron deficiency, iron deficiency anaemia, and kidney disease. Its portfolio spans intravenous and oral iron therapies, potassium and phosphate binders, erythropoiesis-stimulating agents, and specialty nephrology drugs, with products approved in up to 87 countries and marketed across more than 100 countries. The company operates via the joint venture Vifor Fresenius Medical Care Renal Pharma and in-licenses products from partners such as Roche and Pfizer.

Is Vifor Pharma a public or private company?

Vifor Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Vifor Pharma founded?

Vifor Pharma was founded in 1872. It employs 1,001 to 5,000 people.

Where is Vifor Pharma based?

Vifor Pharma is headquartered in Glattbrugg, Switzerland, in the Europe region.

Who are Vifor Pharma's main competitors?

Direct peers on record are Akebia Therapeutics, Fresenius Medical Care, Amgen, Ardelyx, AstraZeneca, Pharmacosmos and Daiichi Sankyo / American Regent. Broad incumbents are Sanofi, Roche and GSK.

Does Vifor Pharma have an API?

No public API is recorded for Vifor Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NzzVier Jahre nach dem Kauf von Vifor: CSL schreibt Milliarden abAustralian pharmaceutical company CSL recorded a $4.1 billion write-down on its acquisition of Swiss firm Vifor due to intensified competition and declining sales of the iron therapy Ferinject. The loss was accompanied by significant restructuring measures, including global workforce reductions and the closure of research facilities in Switzerland. Despite the impairment, CSL's stock price rose sharply as investors responded positively to cost-cutting progress and stable performance in the core immunoglobulin business.AInvestCSL: pretax impairments of $5.5B in 2H of FY26CSL Ltd announced approximately $5 billion in pre-tax asset impairments, largely stemming from its 2022 Vifor Pharma acquisition and underused assets. The company simultaneously revised its FY26 revenue guidance downward to $15.2 billion due to inventory normalization in the U.S., market declines in China, and geopolitical headwinds.BioXconomyPharma pricing evolves with IRA and new rulesRosalind Davis, head of government pricing and market access at CSL Vifor Pharma, is scheduled to present at the Life Sciences Pricing and Contracting USA conference on pharmaceutical pricing evolution and operational best practices. The article discusses how the Inflation Reduction Act has transformed the industry landscape, replacing the Medicare Part D coverage gap with new programs including the Manufacturer Discount Program, Inflation Rebates, and Part B Discarded Drug Program, while also introducing compliance complexities around bona fide service fees documentation for 2026. Davis emphasizes that pharma pricing has shifted away from double-digit WAC increases due to state price transparency laws, public pressure, and structural consequences including price protection clauses in PBM agreements.YahooIron Drugs Market Analysis and Outlook (2018-2030) by Drug Type, Indication, Distribution Channel, End User, Formulation and RegionThe iron drugs market is projected to grow from $2.84 billion in 2024 to $4.16 billion by 2030, a 6.57% CAGR. Growth is driven by next-gen formulations and precision medicine, while 2025 U.S. tariffs pressure supply chains. Key players include Vifor Pharma and Fresenius Kabi.Straits ResearchIV and Oral Iron Drugs Market Size, Share And Growth Report, 2031The global IV and oral iron drugs market was valued at USD 6.25 billion in 2022 and is projected to reach USD 16.51 billion by 2031, growing at a CAGR of 11.43%. Key players such as Vifor Pharma, Daiichi Sankyo, and American Regent are driving growth through strategic collaborations, licensing agreements, and the expansion of branded IV iron therapies, particularly in North America and Europe. Market dynamics are influenced by the rising prevalence of iron deficiency anemia and chronic kidney disease, alongside restraints from alternative treatment options and adverse effects associated with long-term iron therapy.AETOSWireCancellation of remaining publicly held registered shares of Vifor Pharma AGVifor Pharma AG's Commercial Court St. Gallen cancelled all remaining publicly held registered shares, effective and published in the Swiss Official Gazette. The last trading day was 22 December 2022, delisting on 23 December 2022, with compensation of USD 179.25 per share payable on 28 December 2022.BioSpaceCancellation of remaining publicly held registered shares of Vifor Pharma AGVifor Pharma AG's Commercial Court St. Gallen cancelled all remaining publicly held registered shares, effective 23 December 2022. Each cancelled share is compensated at USD 179.25, with settlement on 28 December 2022. The delisting date was 23 December 2022.Australian Financial ReviewCSL know-how to drive Vifor growthCSL plans to leverage its 106-year experience to grow Vifor's iron deficiency and renal products business, unlocking scale and new use cases. The $11.7 billion acquisition's real value lies in the combined R&D portfolios, according to CSL CEO Paul Perreault.Australian Financial ReviewCSL to lift the hood on its $18.8b Vifor acquisitionCSL will present its strategy for the acquired Vifor business on Monday, the first detailed overview since the December acquisition announcement. The $11.7 billion purchase of the Swiss renal therapy and iron deficiency products business has left analysts and investors speculating about the reasoning.BioSpaceApproval of delisting of Vifor Pharma AG’s registered sharesVifor Pharma AG received approval from SIX Exchange Regulation to delist all its registered shares. The delisting will occur after a legally binding court decision cancels the remaining publicly held shares. The last trading day and delisting date will be set in consultation with Vifor.